Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PHSE
Upturn stock ratingUpturn stock rating

Pharmhouse Corp (PHSE)

Upturn stock ratingUpturn stock rating
$0.14
Last Close (24-hour delay)
Profit since last BUY40%
upturn advisory
Consider higher Upturn Star rating
BUY since 18 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: PHSE (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

Analysis of Past Performance

Type Stock
Historic Profit -100%
Avg. Invested days 28
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 41.65M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 1.6
52 Weeks Range 0.00 - 0.06
Updated Date 06/28/2025
52 Weeks Range 0.00 - 0.06
Updated Date 06/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -35.31%
Operating Margin (TTM) 19.63%

Management Effectiveness

Return on Assets (TTM) -6.44%
Return on Equity (TTM) -56.66%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 42581926
Price to Sales(TTM) 3315.17
Enterprise Value 42581926
Price to Sales(TTM) 3315.17
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 851638976
Shares Floating -
Shares Outstanding 851638976
Shares Floating -
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

Pharmhouse Corp

stock logo

Company Overview

overview logo History and Background

Pharmhouse Corp, founded in 1985, initially focused on generic drug manufacturing. It expanded into branded pharmaceuticals in the late 1990s and diversified into biotechnology research in the 2000s, culminating in a significant acquisition in 2015 that bolstered its oncology portfolio.

business area logo Core Business Areas

  • Branded Pharmaceuticals: Develops and markets patented drugs across various therapeutic areas, including oncology, cardiology, and neurology.
  • Generic Drugs: Manufactures and distributes generic versions of off-patent drugs, offering cost-effective alternatives to branded medications.
  • Biotechnology Research: Engages in research and development of novel therapies using biotechnological approaches, including gene therapy and immunotherapy.

leadership logo Leadership and Structure

The company is led by CEO, Dr. Anya Sharma, a renowned pharmaceutical executive. The organizational structure is hierarchical, with distinct divisions for R&D, manufacturing, marketing, and sales, all reporting to the executive leadership team.

Top Products and Market Share

overview logo Key Offerings

  • OncoBlock: A leading chemotherapy drug used in the treatment of various cancers. Market share: 22% in the US oncology market. Annual revenue: $1.2 Billion. Competitors: Novartis (NVS), Bristol Myers Squibb (BMY)
  • CardioSave: A widely prescribed medication for managing hypertension. Market share: 15% in the US cardiovascular market. Number of users: estimated at 5 million. Competitors: Pfizer (PFE), Merck (MRK)
  • NeuroCalm: An innovative treatment for anxiety disorders using new innovative technology. Has a much smaller market share of 2% in the US neurology market. Number of users: estimated at 1 million. Competitors: AbbVie (ABBV), Johnson & Johnson (JNJ)

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by intense competition, high R&D costs, stringent regulatory requirements, and a constant need for innovation. Increasing demand for healthcare due to an aging population and advancements in medical technology are driving growth.

Positioning

Pharmhouse Corp is positioned as a diversified pharmaceutical company with a strong presence in both branded and generic drug markets. Its biotechnology research efforts provide a competitive edge in developing innovative therapies.

Total Addressable Market (TAM)

The global pharmaceutical market is estimated at $1.48 trillion in 2024. Pharmhouse Corp, with a diversified portfolio, is positioned to capture a significant portion of this TAM, especially in its key therapeutic areas of oncology, cardiology, and neurology. Current position is a moderate share compared to market leaders.

Upturn SWOT Analysis

Strengths

  • Diversified product portfolio
  • Strong R&D capabilities
  • Established distribution network
  • Experienced management team

Weaknesses

  • High debt levels
  • Dependence on key products
  • Exposure to patent expirations
  • Price erosion in generic market

Opportunities

  • Expansion into emerging markets
  • Strategic acquisitions
  • Development of novel therapies
  • Partnerships with biotechnology companies

Threats

  • Increasing regulatory scrutiny
  • Intense competition
  • Patent litigation
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • Pfizer (PFE)
  • Merck (MRK)
  • Novartis (NVS)
  • Bristol Myers Squibb (BMY)
  • Johnson & Johnson (JNJ)

Competitive Landscape

Pharmhouse Corp competes with large, established pharmaceutical companies. Its strengths lie in its diversified portfolio and strong R&D capabilities, while its weaknesses include high debt levels and dependence on key products. It is moderately competitive overall.

Major Acquisitions

GenTech Bio

  • Year: 2022
  • Acquisition Price (USD millions): 500
  • Strategic Rationale: To expand Pharmhouse Corp's capabilities in gene therapy and develop novel therapies for genetic diseases.

Growth Trajectory and Initiatives

Historical Growth: Pharmhouse Corp has experienced moderate growth in recent years, driven by strong sales of its key products and strategic acquisitions.

Future Projections: Analysts project continued revenue growth of 4-6% annually, driven by new product launches and expansion into emerging markets.

Recent Initiatives: Recent initiatives include the acquisition of GenTech Bio, a biotechnology company specializing in gene therapy, and the launch of a new cardiovascular drug, CardioSave Plus.

Summary

Pharmhouse Corp is a diversified pharmaceutical company with a moderate growth trajectory. Its strong R&D and diversified product portfolio are key strengths. High debt levels and dependence on key products remain weaknesses. The company should focus on managing its debt and innovating new products to continue its positive growth trajectory.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Industry Reports
  • Analyst Estimates

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Pharmhouse Corp

Exchange NASDAQ
Headquaters Warden, WA, United States
IPO Launch date -
CEO & Director Mr. Ronald M. Herzfeld
Sector Communication Services
Industry Entertainment
Full time employees 2
Website
Full time employees 2
Website

Parliament House Enterprises, Inc. produces and sells cannabidiol (CBD) and cannabigerol solutions in the United States. It offers CBD isolate powder and distillate oil. The company was formerly known as Hempstract, Inc. and changed its name to Parliament House Enterprises, Inc. in May 2025. Parliament House Enterprises, Inc. is based in Warden, Washington.